A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 222 participants.

Also called NCT06647745

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 222 participants (enrolled count) (from the registry)
Sponsor
THPharm Corp. (from the registry)
Registry
  • NCT NCT06647745
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea, Thailand (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06647745. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-10 (actual); primary completion 2026-11-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
Acronym
THP-001-031
Condition
Hypertension
Intervention (Drug)
THP-00101
Intervention (Drug)
THP-00102
Intervention (Drug)
THP-00103
Intervention (Drug)
THP-00104
Intervention (Drug)
THP-00105
Intervention (Drug)
THP-00106
Lead sponsor
THPharm Corp. (class: industry)

Record details

Record id
cardio:ct-nct06647745
Content hash
8af0ff5fde0caba932f90518d88582aa03d0ae5236796c2d368b02fb1397d0f6